SGCB and congestive heart failure: Interestingly, both Bayer and Cyclerion conducted studies with the sGC stimulators vericiguat and praliciguat in chronic heart failure patients with preserved ejection fraction (HFpEF): the Vitality HFpEF study with vericiguat (Butler et al. 2019) and the Capacity HFpEF study with praliciguat (Udelson et al. 2020).